Condition: Breast Cancer · Sponsor: Daiichi Sankyo
This study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor \[HR\]-negative and HR-positive) unresectable and/or metastatic breast cancer.
This description comes directly from the study's public registry record.
(US Sites) Daiichi Sankyo Contact for Clinical Trial Information · 908-992-6400 · CTRinfo@dsi.com
(Asia Sites) Daiichi Sankyo Contact for Clinical Trial Information · +81-3-6225-1111 (M-F 9-5 JST) · dsclinicaltrial@daiichisankyo.co.jp
Always discuss trial participation with your own doctor first.
| Mount Sinai Medical Center | Miami Beach, Florida, United States | Terminated |
| USF College of Medicine | Tampa, Florida, United States | Withdrawn |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Beth Israel Lahey Health | Burlington, Massachusetts, United States | Withdrawn |
| Overlook Medical Center | Summit, New Jersey, United States | Recruiting |
| Mater Hospital Sydney | North Sydney, New South Wales, Australia | Terminated |
| Monash Medical Centre Moorabbin | East Bentleigh, Victoria, Australia | Terminated |
| GenesisCare St Andrews Hospital | Adelaide, Australia | Terminated |
| Fiona Stanley Hospital | Murdoch, Australia | Withdrawn |
| Institut Jules Bordet | Anderlecht, Belgium | Recruiting |
| GZA Ziekenhuizen | Antwerp, Belgium | Withdrawn |
| Universitair Ziekenhuis Brussel | Brussels, Belgium | Withdrawn |
+ 76 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05950945